Furthermore, we also demonstrated that the expression of DSCC1 was positively correlated with multiple genetic mutations which drive cancer development, including TP53, TTN, CSMD, and etc. Thus, this study highlights that DSCC1 promotes cancer progression of LUAD, and DSCC1 suppression might be a novel therapeutics option for treating LUAD. The gene discussed is TTN; the disease is cancer.